Market Research Report
Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution
|Published by||GBI Research||Product code||241634|
|Published||Content info||129 Pages
|Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution|
|Published: May 18, 2012||Content info: 129 Pages||
This publication has been discontinued on February 2, 2017.
GBI Research, the leading business intelligence provider, has released its latest research "Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution". The report provides in-depth analysis of drivers and barriers that impact the global cardiovascular disorders market. The report analyzes the generics market for cardiovascular disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns are forecast until 2018 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
The global generics market cardiovascular drugs is expected to grow rapidly due to the growing dyslipdemia, thrombosis and hypertension populations in the developed countries, as well as patent expiries of major blockbusters such as Lipitor (atorvastatin), Plavix (clopidigrel) and Diovan (valsartan). The patent expiries of these blockbuster drugs will trigger generic competition in the cardiovascular therapeutics market, making it more competitive.
In 2010, the generics market for cardiovascular drugs was estimated at $20.5 billion, indicating a year on year decline of 0.9% from 2004-2010. Patent expiries of the leading antiplatelets/antithrombotics such as Plavix (clopidigrel) and Lovenox (enoxaparin) and lipid lowering blockbuster Lipitor in 2010-2012, resulting in uptake of generics, is expected to cause the market to increase significantly from 2010 to 2018.